
Annual report 2024
added 03-21-2026
Nano-X Imaging Ltd. EBITDA 2011-2026 | NNOX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Nano-X Imaging Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -61 M | -43.7 M | -22.5 M | -1.87 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.87 M | -61 M | -32.3 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abbott Laboratories
ABT
|
9.49 B | $ 102.87 | 0.48 % | $ 179 B | ||
|
Align Technology
ALGN
|
753 M | $ 170.6 | -1.23 % | $ 12.8 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Alphatec Holdings
ATEC
|
-4.64 M | $ 10.83 | -3.82 % | $ 1.63 B | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
AxoGen
AXGN
|
-1.19 M | $ 34.44 | 2.56 % | $ 1.59 B | ||
|
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | ||
|
ClearPoint Neuro
CLPT
|
-23.4 M | $ 9.37 | 2.52 % | $ 265 M | ||
|
Accuray Incorporated
ARAY
|
14 M | $ 0.42 | 6.82 % | $ 43.2 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | ||
|
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.58 | 6.52 % | $ 36.1 M | ||
|
Delcath Systems
DCTH
|
898 K | $ 9.63 | 0.94 % | $ 345 M | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
10.7 M | $ 23.29 | -1.52 % | $ 197 M | ||
|
Bruker Corporation
BRKR
|
437 M | $ 36.76 | 1.88 % | $ 5.48 K | ||
|
Boston Scientific Corporation
BSX
|
4.98 B | $ 62.82 | 1.32 % | $ 93 B | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 81.05 | -0.26 % | $ 47.4 B | ||
|
CONMED Corporation
CNMD
|
120 M | $ 34.79 | -2.08 % | $ 1.08 B | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Aethlon Medical
AEMD
|
-9 M | $ 2.12 | -1.4 % | $ 3.31 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 12.03 | 1.43 % | $ 1.63 B | ||
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.86 | 9.41 % | $ 1.13 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
70.8 M | $ 9.53 | -0.42 % | $ 734 M | ||
|
Inogen
INGN
|
-9.55 M | $ 6.21 | -0.96 % | $ 165 M | ||
|
Inspire Medical Systems
INSP
|
64.9 M | $ 54.99 | 2.52 % | $ 1.61 B | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 16.06 | -1.41 % | $ 377 M | ||
|
IRIDEX Corporation
IRIX
|
-2.05 M | $ 0.98 | 3.17 % | $ 16.6 M | ||
|
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | ||
|
Integer Holdings Corporation
ITGR
|
352 M | $ 86.85 | 0.47 % | $ 3.02 B | ||
|
LivaNova PLC
LIVN
|
228 M | $ 63.79 | -1.3 % | $ 3.48 B | ||
|
LENSAR
LNSR
|
-21 M | $ 6.06 | 1.51 % | $ 72.5 M |